We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025 (unless Genmab terminates or suspends the program).

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. Analyst Price Forecast Suggests 454.75% Upside As of March 4 ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...